Compare AU
Compare EMKT vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the VanEck MSCI Multifactor Em Markets Equity ETF (EMKT) and the Global X S&P Biotech ETF (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
EMKT | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 194 | 76 |
Median incremental investment | $1,048.54 | $640.11 |
Median investment frequency | Monthly | Monthly |
Median total investment | $3,801.65 | $1,242.60 |
Average age group | > 35 | > 35 |
Key Summary
EMKT | CURE | |
|---|---|---|
Strategy | EMKT.AX was created on 2018-04-10 by VanEck. The fund's investment portfolio concentrates primarily on total market equity. The VanEck MSCI Multifactor Emerging Markets Equity ETF (EMKT.AX) invests in a diversified portfolio of emerging markets listed securities with the aim of providing investment returns, before fees and other costs, which track the performance of the MSCI Emerging Markets Diversified MultipleFactor Index (AUD) (EMKT.AX Index). | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | Taiwan Semiconductor Manufacturing Co Ltd (7.51 %) Emaar Properties PJSC (3.05 %) Tencent Holdings Ltd (2.81 %) | Exact Sciences Corp (3.25 %) Alnylam Pharmaceuticals Inc (3.03 %) Neurocrine Biosciences Inc (2.99 %) |
Top 3 industries | Information Technology (49.50 %) Consumer Discretionary (13.38 %) Materials (12.51 %) | Health Care (100.00 %) Other (10.24 %) |
Top 3 countries | India (23.86 %) Taiwan (23.66 %) China (21.17 %) | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) |
Management fee | 0.69 % | 0.45 % |
Key Summary
EMKT | CURE | |
|---|---|---|
Issuer | VanEck | Global X |
Tracking index | MSCI Emerging Markets Diversified Multiple-Factor Index - AUD | S&P Biotechnology Select Industry |
Asset class | ETF | ETF |
Management fee | 0.69 % | 0.45 % |
Price | $27.35 | $41.42 |
Size | $220.401 million | $28.877 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 3.31 % | 4.24 % |
Market | ASX | ASX |
First listed date | 12/04/2018 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
EMKT | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 194 | 76 |
Median incremental investment | $1,048.54 | $640.11 |
Median investment frequency | Monthly | Monthly |
Median total investment | $3,801.65 | $1,242.60 |
Average age group | > 35 | > 35 |
Pros and Cons
EMKT | CURE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
EMKT | CURE |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Higher management fee | Lower management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |